At the news
? BULLISHIMPACT 8/10 8-K filed Jul 24, 2026 at 17:01 ET
Outlook Therapeutics announced FDA approval of LYTENAVA (bevacizumab-vikg) for wet AMD, the first and only FDA-approved ophthalmic formulation of bevacizumab. The company expects 12 years of BPCIA exclusivity and is launching into the ~$8.5B U.S. retina market. This is a transformative, binary-clearance event for a pre-revenue biotech, removing the primary regulatory overhang and enabling commercial revenue generation.
- FDA approved LYTENAVA (bevacizumab-vikg) for neovascular (wet) age-related macular degeneration
- First and only FDA-approved ophthalmic formulation of bevacizumab in the U.S.
- Company anticipates 12 years of Reference Product Exclusivity under the BPCIA
- U.S. anti-VEGF retina market estimated at approximately $8.5 billion annually
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access